Sanofi
A global biopharmaceutical company that discovers, develops, and markets medicines and vaccines.
SAN | PA
Overview
Corporate Details
- ISIN(s):
- FR0000120578 (+39 more)
- LEI:
- 549300E9PC51EN656011
- Country:
- France
- Address:
- 46 AVENUE DE LA GRANDE ARMEE, 75017 PARIS
- Sector:
- Manufacturing
Description
Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2022-10-28 07:30 |
Press Release: Continued strong growth in Q3 with key regulatory milestones ach…
|
English | PDF • 363.8 KB | ||
| 2022-10-28 07:30 |
Communiqué de Presse : Forte performance au T3 et avancées règlementaires clés
|
French | PDF • 370.9 KB | ||
| 2022-10-18 08:58 |
Franchissement de seuil
|
French | PDF • 260.9 KB | ||
| 2022-10-17 19:35 |
6-K
|
English | ZIP • 33.5 KB | ||
| 2022-10-13 21:58 |
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Septe…
|
French | PDF • 118.6 KB | ||
| 2022-10-13 21:58 |
Sanofi: Information concerning the total number of voting rights and shares - S…
|
English | PDF • 142.0 KB | ||
| 2022-10-11 07:00 |
Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data presented at UE…
|
English | PDF • 164.3 KB | ||
| 2022-10-03 17:24 |
6-K
|
English | ZIP • 35.7 KB | ||
| 2022-09-29 00:05 |
Press Release: Dupixent® (dupilumab) approved by FDA as the first and only trea…
|
English | PDF • 176.3 KB | ||
| 2022-09-29 00:05 |
Communiqué de presse: Dupixent® (dupilumab), premier et seul médicament approuv…
|
French | PDF • 179.2 KB | ||
| 2022-09-28 07:30 |
Communiqué de presse : Mise en ligne du document «Q3 2022 Memorandum for modell…
|
French | PDF • 114.0 KB | ||
| 2022-09-28 07:30 |
Press Release: Availability of the Q3 2022 Memorandum for modelling purposes
|
English | PDF • 120.2 KB | ||
| 2022-09-22 15:49 |
6-K
|
English | ZIP • 34.7 KB | ||
| 2022-09-16 08:00 |
Communiqué de presse: Le CHMP recommande l’approbation de Beyfortus® (nirsevima…
|
French | PDF • 198.9 KB | ||
| 2022-09-16 08:00 |
Press Release: CHMP recommends approval of Beyfortus® (nirsevimab) for preventi…
|
English | PDF • 185.0 KB |
Automate Your Workflow. Get a real-time feed of all Sanofi filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Sanofi
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Sanofi via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-02 | N/A | Other | Buy | 71,423 | N/A |
| 2024-04-26 | N/A | Other | Buy | 1,000 | 91,380.00 EUR |
| 2023-06-09 | N/A | Other | Buy | 9 | 856.04 EUR |
| 2023-05-02 | N/A | Other | Buy | 65,205 | 6,364,008.00 EUR |
| 2023-05-02 | N/A | Other | Buy | 500 | 48,835.00 EUR |
Peer Companies
